Posts by cowic

The SPAEN Clinical Sarcoma Research Paper on “The challenge of sarcomas: the patient advocacy group perspective” has been written by Roger Wilson, SPAEN honorary president and a sarcoma patient advocate for more than 20 years. The patient advocacy agenda covers every aspect of cancer treatment and care. This inevitably means that this review covers almost…

Soon to come

The most common bone sarcomas are osteosarcoma, Ewing’s sarcoma, chondrosarcoma, giant cell tumours and chordomas, with osteosarcomas and chondrosarcomas being the most frequent, accounting for over half of all the malignant bone tumour diagnoses. Osteosarcoma is the most frequent primary cancer of bone. It is estimated that per year, 2-3 persons in one million are…

10 FACTS – STRASS Trial WHO is the trial for? •    Patients with histologically confirmed retroperitoneal sarcoma (RPS)•    No metastasis •    Previously untreated •    Tumor must be operable, suitable for radiotherapy and radiologically measurable (RECIST 1.1)•    Overall health status of the patient has to be good (WHO performance status 0-2)•    No other malignant tumor disease…

10 Questions About Trials to Ask Your Doctor Taking part in a clinical trial can be a good choice but it is often hard to find a clinical trial that is right for you. To find clinical trials: Talk to your doctor who may have a clinical trial available at your hospital Ask if there are…

WECAN Academy 2019 The WECAN Academy 2019 combined two leading capacity building programmes in patient advocacy: WECAN Smart Start: Starting and Building a National Non-Profit Patient Group focused on “beginners” in patient advocacy, and the WECAN Masterclass on Patient Advocacy  on experienced patient advocacy leaders. These two 3-day training programmes were held for 6-9 July…

Please find below reports from the most important congresses and projects:   ESSO 39The annual meeting of the European Society of Surgical Oncology was held this year in Rotterdam from 8 until 10 October. Although ESSO covers the entire field of cancers, it was of interest to SPAEN for a number of reasons. First because…